CCT128930は一種の有効的で、ATP競争性的で、選択性のAkt2阻害剤で、無細胞試験でIC50値が6 nMになって、Akt2に作用する選択性が緊密関連のPKAキナーゼに作用する選択性より28倍高くなります。

価格 在庫  
USD 214 あり
USD 289 あり
USD 403 あり
USD 1222 あり

CCT128930 化学構造
分子量: 341.84





  • Compare Akt Inhibitors
  • 研究分野
  • CCT128930のメカニズム



製品説明 CCT128930は一種の有効的で、ATP競争性的で、選択性のAkt2阻害剤で、無細胞試験でIC50値が6 nMになって、Akt2に作用する選択性が緊密関連のPKAキナーゼに作用する選択性より28倍高くなります。
ターゲット Akt2 PKA p70S6K
IC50 6 nM 168 nM 120 nM [1]
In vitro試験 CCT128930 exhibits marked antiproliferative activity against PTEN-deficient human tumor cell lines including U87MG human glioblastoma cells, LNCaP human prostate cancer cells and PC3 human prostate cancer cells with GI50 of 6.3 μM, 0.35 μM and 1.9 μM, respectively. Furthermore, CCT128930 causes a G1 arrest in PTEN-null U87MG human glioblastoma cells and Akt pathway blockade. [1]
In vivo試験 CCT128930 at 25 mg/kg i.p. shows a marked antitumor effect in established PTEN-null U87MG human glioblastoma xenografts with a treated:control (T/C) ratio of 48% on day 12. In HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts, CCT128930 at 40 mg/kg also produces a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. CCT128930 administrated via i.v. reaches a peak concentration of 6.4 μM in plasma and is eliminated with a relatively short half-life, high volume of distribution, and rapid clearance, giving an area under the curve AUC0-∞ of 4.6 μM h. CCT128930 administrated via i.p. leads to the peak plasma drug concentration of 1.3 μM and the corresponding AUC0-∞ of 1.3 μM·h. Oral CCT128930 administration leads to the peak plasma concentration of only 0.43 μM and a correspondingly low AUC0-∞ of 0.4 μM·h. [1]

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Kinase assays Profiling against 50 different human kinases is carried out using 10 μM CCT128930 at an ATP concentration equivalent to the Km for each enzyme.

細胞アッセイ: [1]

細胞株 U87MG, LNCaP and PC3 cells
濃度 0-18.9 μM
反応時間 48 hours
実験の流れ Cells are seeded in 96-well plates and allowed to attach for 36 hours to ensure exponential growth prior to treatment. In vitro antiproliferative activity is determined using a 96-hour SRB assay. TCA-fixed cells are stained for 30 minutes with 0.4% (wt/vol) SRB dissolved in 1% acetic acid. At the end of the staining period, SRB is removed and cultures are quickly rinsed four times with 1% acetic acid to remove unbound dye. The acetic acid is poured directly into the culture wells from a beaker. This procedure permits rinsing to be performed quickly so that desorption of protein-bound dye does not occur. Residual wash solution is removed by sharply flicking plates over a sink, which ensures the complete removal of rinsing solution. Because of the strong capillary action in 96-well plates, draining by gravity alone often fails to remove the rinse solution when plates are simply inverted. After being rinsed, the cultures are air dried until no standing moisture is visible. Bound dye is solubilized with 10 mM unbuffered Tris base (pH 10.5) for 5 minutes on a gyratory shaker. OD is read in either a UVmax microtiter plate reader or a Beckman DU-70 spectrophotometer. For maximum sensitivity, OD is measured at 564 nm. Because readings are linear with dye concentrations only below 1.8 OD units, however, suboptimal wavelengths are generally used, so that all samples in an experiment remains within the linear OD range. With most cell lines, wavelengths of approximately 490-530 nm works well for this purpose.

動物実験: [1]

動物モデル PTEN-null U87MG human glioblastoma cells are injected subcutaneously (s.c.) in the right flank of female CrTacNCr-Fox1nu mice. For HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts, cells are administered s.c. in medium supplemented with M
製剤 CCT128930 is dissolved in 10% DMSO, 5% Tween 20, and 85% saline.
投薬量 ≤50 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download CCT128930 SDF
分子量 341.84


CAS No. 885499-61-6
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 68 mg/mL (198.92 mM)
Ethanol 6 mg/mL (17.55 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 11 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine

文献中の引用 (4)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related Akt 阻害剤

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt阻害剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • AT13148

    AT13148は一種ATP競争性的で、多AGCキナーゼ経口阻害剤で、Akt1/2/3、p70S6K、PKAとROCKI/II的IC50値が38 nM/402 nM/50 nM、8 nM、3 nMと6 nM/4 nMそれぞれに分かれます。臨床1期。

  • SC79


  • TIC10


  • MK-2206 2HCl

    MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • AZD5363

    AZD5363はAkt(Akt1/Akt2/3)の全ての亜型を有効に抑制し、無細胞試験で IC50値が3 nM/8 nM/8 nMそれぞれに分かれて、P70S6K/PKAに類似の抑制作用をしていますが、ROCK1/2に低い抑制活性を表します。臨床2期。

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • GDC-0068

    Ipatasertib (GDC-0068)は一種の高選択性のパン(pan)Akt阻害剤で、Akt1/2/3に作用して、無細胞試験でIC50値が 5 nM/18 nM/8 nMそれぞれに分かれて、PKAに作用する選択性より620倍が高くなります。臨床2期。

  • GSK690693

    GSK690693は一種のパン(pan)Akt阻害剤で、無細胞試験でAkt1/2/3に作用する時の IC50値が2 nM/13 nM/9 nMそれぞれに分かれます。GSK690693はAGCキナーゼ家族(PKA、PrkXとPKC)イソ酵素にも敏感です。臨床1期。

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401)は一種の新たなAkt阻害剤で、MM.1S細胞の中で IC50値が4.7 μMになって、Aktのプレクストリンホモロジードメイン(pleckstrin homology domain)に作用します。臨床3期。

  • A-674563

    A-674563は一種のAkt阻害剤で、無細胞試験でKi値が11 nMになって、PKAに適合に有効していて、Akt1に作用する選択性がPKCに作用する選択性より30倍余り高くなります。

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.


Tags: CCT128930を買う | CCT128930供給者 | CCT128930を購入する | CCT128930費用 | CCT128930生産者 | オーダーCCT128930 | CCT128930代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID